Dermatology

The American Academy of Dermatology (AAD) 2023 Annual Meeting took place last month in New Orleans, Louisiana, and The American Journal of Managed Care® was there to cover the latest news—catch up on what you may have missed.

The lower number needed to treat suggests that ruxolitinib cream may be more effective for patients with atopic dermatitis (AD), according to a poster presented at AMCP 2023.

This year’s most-read articles on dermatology covered the first and only FDA-approved treatment for repigmentation in patients with vitiligo, as well as other therapies for the treatment of acne, hidradenitis suppurativa, and more.

A research letter examined the clinical presentation, disease severity, associated comorbidities, and management of hidradenitis suppurativa in older adults aged 65 years or older.

This American Academy of Dermatology (AAD) Annual Meeting covered a breakthrough therapy for the management of vitiligo, clinical and epidemiological differences of certain dermatologic diseases, and the role of dietary triggers on patient outcomes.

Non-White patients with hidradenitis suppurativa reported longer delay in diagnosis than their White counterparts. In addition, Black patients did not receive dermatologic care as early in their disease course as other racial groups.

Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of Dermatology at the University of California Davis in Sacramento, spoke on the advancement in precision medicine within dermatology and what role genetics, research, and immunology can have for care management going forward.

Patients with pemphigus reported lower risk of myocardial infarction and stroke, among other cardiovascular and metabolic outcomes, when treated with rituximab compared with the first-line corticosteroid-sparing agents azathioprine and mycophenolate mofetil.

Female allopathic medical students pursuing careers in dermatology were less likely than those pursuing other specialties to be from racial and ethnic groups underrepresented in medicine or be a sexual minority, with a lack of interest in underserved care and public health shown overall.

Patient-reported outcome (PRO) measures were included in approximately one-half of acne vulgaris and rosacea randomized controlled trials, despite their utility in capturing the patient perspective.

Researchers found that different factors can negatively impact the Dermatology Life Quality Index scores for adults and adolescents with acne.

Korean patients who had more advanced chronic kidney disease (CKD), defined by estimated glomerular filtration rate of 29 or less vs 90 or more, and presence of proteinuria were associated with greater risk of prurigo nodularis.

Representation of Black and Latinx resident trainees was shown to be worse in dermatology vs other specialties, and annual representation in dermatology remained unchanged between 2005 and 2020.

More than a third (42.8%) of pediatric patients with hidradenitis suppurativa did not meet all major diagnostic criteria at the time of diagnosis, particularly due to failure to fulfill the recurrence interval criterion (2 or more lesions within 6 months).

Patients with hidradenitis suppurativa who reported feelings of stigmatization due to their condition had worse quality of life and higher levels of depression and social anxiety vs those not reporting feelings of stigmatization.

An analysis of Medicaid coverage found that Mississippi was the only state not to provide coverage for human papillomavirus (HPV) vaccination in adults aged 27 to 45 years.

Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of Dermatology at the University of California Davis in Sacramento, spoke on challenges in the management of hidradenitis suppurativa (HS), as well as promising therapies in the pipeline that target specific pathways suggested to play a role in the pathogenesis and pathophysiology of the disease.

Emergency department (ED) readmission was more common than dermatology follow-up among patients with hidradenitis suppurativa (HS) within 30 and 180 days of initially presenting to the ED, with patients with Medicaid coverage and those who had an opioid prescribed were more likely to return.

Athena Gierbolini, president of Hope for HS, a nonprofit advocacy group for those affected with hidradenitis suppurativa (HS), spoke on common stigmas regarding HS and how clinicians can improve consultation through a culturally sensitive approach.

A recent review found that new methods of treatment for prurigo nodularis had promising results, including approaches that target interleukin 31 and its receptor.

Researchers reviewed clinical features of hidradenitis suppurativa and provided strategies to promote earlier identification, differentiation from common mimickers, and timely referrals for multidisciplinary management.

Athena Gierbolini, president of Hope for HS, a nonprofit advocacy group for those affected with hidradenitis suppurativa (HS), discusses current knowledge on the impact of diet and other holistic care strategies in the management of HS.

Approximately 1 in 10 patients with hidradenitis suppurativa (HS) experienced complications related to surgery for HS management, in which extensive resection, using skin flaps or skin grafts as a closure method, was associated with a higher incidence of complications.

Athena Gierbolini, president of Hope for HS, a nonprofit advocacy group for those affected by hidradenitis suppurativa (HS), discussed several pressing issues that warrant consideration to improve the care management of HS.

Black patients with hidradenitis suppurativa were more likely to experience greater disease severity, emergency department visits, hospitalizations, and surgeries than non-Hispanic White patients.

Tobacco smoking, depression, and increasing number of comorbidities were associated with reduced treatment satisfaction among patients with hidradenitis suppurativa.

Athena Gierbolini, president of Hope for HS, a nonprofit advocacy group for those affected by hidradenitis suppurativa (HS), spoke on the surgical and therapeutic interventions she’s had for the management of HS.

Athena Gierbolini, president of Hope for HS, a nonprofit advocacy group for those affected by hidradenitis suppurativa (HS), discussed the misconceptions she faced from clinicians regarding her clinical symptoms of HS prior to diagnosis.

SUNSHINE and SUNRISE trial data will be submitted to the FDA as part of Novartis’ Biologics License Application (BLA) for secukinumab in hidradenitis suppurativa.

Athena Gierbolini, president of Hope for HS, a nonprofit advocacy group for those affected with hidradenitis suppurativa (HS), speaks on the quality of life burden she has experienced during her HS disease journey.